drugset
drugset / Trial / NCT02772107

Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer

NCT02772107 ↗

Phase 2/3 Unknown 132 enrolled Chinese PLA General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Temozolomide may delay progression in sequence with chemotherapy. This open-label, randomized,multicenter phase II trial was designed to evaluate the role of Temozolomide following 4 or 6 cycles of platinum-based first-line chemotherapy in patients with newly diagnosed estensive-stage SCLC.

Timeline

Start
2015-12
Primary completion
2017-06
Completion
2018-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 150 mg/m2 Oral
Background Carboplatin Small molecule 5 unknown —
Background Cisplatin Other / unclassified 75 mg/m2 —
Background Etoposide Small molecule 100 mg/m2 —

Indications

small cell lung carcinoma